Teaching Tolerance to Address Autoimmune Diseases episode artwork

EPISODE · Jul 24, 2024 · 36 MIN

Teaching Tolerance to Address Autoimmune Diseases

from The Bio Report · host Levine Media Group

The traditional approach to treating autoimmune disease has relied on ways to suppress the immune system. COUR Pharmaceuticals is developing first-in-class therapies that instead seek to reprogram the immune system to create antigen-specific tolerance. We spoke to COUR CEO John Puisis and COUR Vice President of Research Adam Elhofy, about how the company’s immune-modifying nanoparticles work, how the approach preserves the immune response, and its partnership with Takeda focused on celiac disease.

COUR CEO John Puisis and COUR Vice President of Research Adam Elhofy discuss how the company’s immune-modifying nanoparticles work, how the approach preserves the immune response, and its partnership with Takeda focused on celiac disease.

NOW PLAYING

Teaching Tolerance to Address Autoimmune Diseases

0:00 36:25

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Bio Report?

This episode is 36 minutes long.

When was this The Bio Report episode published?

This episode was published on July 24, 2024.

What is this episode about?

The traditional approach to treating autoimmune disease has relied on ways to suppress the immune system. COUR Pharmaceuticals is developing first-in-class therapies that instead seek to reprogram the immune system to create antigen-specific...

Can I download this The Bio Report episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!